Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company’s lead dr...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -3.5x | ||
| Revenue | 683 K | ||
| Net Income to Company | -45.431 M |
| CRDF | Peers | Sector | |
|---|---|---|---|
Market Cap | 158.3 M | 267.4 M | 59.688 M |
Price % of 52 Week High | 43.5% | 46.9% | 57.5% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -30.6% | -13.2% | -0.7% |
1 Year Price Total Return | -58.0% | -33.7% | -16.5% |
Beta (5 Year) | 1.73 | 1.33 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 0.39 | 0.49 | 0.68 | 0.16 | 0.15 |
| Operating Income | (40) | (45) | (49) | (10) | (13) |
| Net Profit | (39) | (41) | (45) | (9.34) | (12) |
| Diluted EPS | -0.89 | -0.93 | -0.95 | -0.21 | -0.22 |
| EBITDA | (40) | (45) | (48) | (10) | (12) |
| Balance Sheet | |||||
| Cash & ST Invest. | 105 | 75 | 92 | 75 | 92 |
| Current Assets | 111 | 77 | 95 | 77 | 95 |
| Total Assets | 116 | 82 | 97 | 82 | 97 |
| Current Liabilities | 7.81 | 10 | 13 | 10 | 13 |
| Total Liabilities | 9.85 | 12 | 14 | 12 | 14 |
| Total Equity | 106 | 70 | 83 | 70 | 83 |
| Total Debt | 2.71 | 2.15 | 1.52 | 2.15 | 1.52 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (34) | (31) | (38) | (7.14) | (10) |
| Cash From Investing | 38 | 36 | 14 | 14 | 4.51 |
| Cash From Financing | 0.07 | 54 | 44 | ||
| Free Cash Flow | (35) | (31) | (38) | (7.15) | (10) |